Canada Bio-Mfg Facility & COVID-19 reserved vaccines

---

Canada signs agreements with Pfizer, Novavax, J&J, & Moderna

• Pfizer, will supply a minimum of 20 million doses of its mRNA-based vaccine candidate, BNT162. Options for obtaining additional doses are under discussion.
• Johnson & Johnson, will supply up to 38 million doses of its vaccine candidate Ad26.COV2.S.
• Novavax, will supply up to 76 million doses of its vaccine candidate NVX-CoV2373.
• Moderna, will supply up to 56 million doses of its vaccine candidate mRNA-1273.

Minister: “Aggressive approach in procuring a portfolio of the most promising vaccine candidates”

According to the Minister of Public Services and Procurement, Anita Anand, “As we continue our work to purchase the supplies and equipment that are necessary to combat the COVID-19 pandemic, we remain equally focused on planning for the future, including securing potential vaccines for Canadians. We are taking an aggressive approach in procuring a portfolio of the most promising vaccine candidates in order to ensure that Canadians will have access to them as quickly as possible once they have been approved.”

Canada already has a $1 billion fund through the ‘Plan to Mobilize Science to fight COVID-19′ to develop a vaccine and treatments, as well as to track the virus. Of this fund, $600 million supports private sector work to develop a vaccine. See Canadian projects in chart below.

None of these vaccines have been approved as yet. They are in various stages of preliminary testing. See chart below.

According to a Canadian government statement, “Health Canada will review the evidence of safety, efficacy, and manufacturing quality for each vaccine to determine whether individual vaccines will be approved for use in Canada, before they are used to vaccinate Canadians.”

Read if you wish the standards testing should meet: COVID-19 vaccine trials should seek worthwhile efficacy Pub: 27 August 2020

 

Two Million Doses per Month Facility in Montreal at NRC

Canada will rapidly establish a new $126 million bio-manufacturing facility at the Human Health Therapeutics Research Centre (at NRC)  in Montréal.

Through a public-private partnership, the new facility according to the Canadian government “will enable the National Research Council of Canada (NRC) to increase vaccine manufacturing to up to two million doses per month by next year”.

“Canada’s Current Status in the Fight Against COVID-19: Cases leveling, CFR Remains High,” says Civil Society biostatistician.

---

January 26, 2022

Population: 38,585,269 adjusted for estimated real COVID-19 deaths

Canada	Cases	Deaths	Cured	Active
Reported:	2,959,499	32,860 1.11% CFR	2,699,170	227,469
Estimate:	15,182,230	53,036 *0.35% IFR	13,846,742	1,166,916

*Inferred IFR is an estimate only. The actual COVID-19 IFR may not be accurately calculated for the entire human race until long after the pandemic has ended.

The IHME estimates excess deaths in Canada to reach much higher than CSPaC estimates.

Canada Provinces	Deaths	CFR%	Cases	Cured	Active
COVID-19 Totals:	32,860	1.11	2,959,499	2,699,170	227,469
Quebec	12,868	1.53	841,413	828,545	0
Ontario	11,068	1.10	1,004,879	932,245	61,566
Alberta	3,483	0.73	477,841	423,201	51,157
BC	2,532	0.80	314,787	265,765	46,490
Manitoba	1,521	1.30	116,770	75,953	39,296
SK	977	0.88	111,447	97,818	12,652
First Nations	593	0.89	66,840	60,790	5,457
NB	215	0.80	26,741	21,165	5,361
Nova Scotia	128	0.37	35,051	30,450	4,473
NL	30	0.21	14,522	11,816	2,676
Yukon	16	0.54	2,981	2,796	169
NWT	15	0.28	5,333	4,356	962
Nunavut	5	0.35	1,439	1,187	247
PEI	2	0.03	6,282	3,860	2,420
Repatriates	0		13	13	0
Sub Totals	32,860	1.11	2,959,499	2,699,170	227,469

Note: Above is region/county Health Unit reports. First Nations data is monitored uniquely but included in provincial totals.

Below: Extensive Estimates using data from multiple sources.

Beta experimental estimates for Canada. Reported + unreported mild + asymptomatic COVID-19 infections.

The total actual number of infections in Canada including all the untested, unreported, asymptomatic infections is likely greater than 15,182,230 (39.35% of the population) including mild and asymptomatic cases. That would mean the estimated inferred average Infection Fatality Rate:
(IFR) is likely around 0.35%

Canadian COVID-19 deaths to 2022-01-26 are estimated to be 53,138 Using estimated IFR of 0.35% which is far below global average IFR.

53,138 (0.35% IFR) is the estimated number of Canadian COVID-19 deaths (based on the inferred IFR) including those deaths unreported as COVID-19). The IHME estimates excess deaths in Canada to reach much higher than CSPaC estimates.

53036 Is the estimated number of Canadian COVID-19 deaths based on a modified universal algorithm which factors more sophisticated public health infrastructure and also fewer available urgent care beds and facilities which is a problem in much of Canada in an emergency measures context.

The closeness of the two numbers derived from unique data and methods suggests their high probability. The blended data of three projections from three different biostatistician labs also confirms the estimates +/- .01%.

It is safe to say that Canadians have endured the grief of losing 53036 family members. Every number has a face. May their memory be forever a blessing to their families and friends.

Canada's advanced public health standards.

Canada and the USA both have a significantly lower than global average Infection Fatality Rate. (influenza has an IFR of .1% or 6 per 100k (2019)).

Ontario, Canada Reports

---

Ontario Regional Public Health Units (PHU) - Reported by Ontario Province.

These reports from the Ontario Province differ significantly from the data reported by individual Public Health Units. CSPaC includes links to each PHU to allow readers of this report to check the latest data from their public health unit. CSPaC has heard the explanation from the province that data is reassigned from one PHU to another based on patient location. That means that patients are taken to the nearest available hospital and not necessarily to a medical facility in their own Public Health Region.

---

Health Unit	Cases	Deaths	CFR	Recoveries	Active
Algoma District	3,379	23	0.7%	2,771	585
Brant County	8,940	54	0.6%	8,101	785
Chatham-Kent	5,707	55	1.0%	5,056	596
Durham Region	48,895	408	0.8%	45,098	3,389
Eastern Ontario	12,060	176	1.5%	10,821	1,063
Grey Bruce	5,193	39	0.8%	4,892	262
Haldimand-Norfolk	6,127	75	1.2%	5,509	543
Haliburton Kawartha Pine Ridge	5,787	75	1.3%	4,990	722
Halton Region	39,119	275	0.7%	36,670	2,174
Hamilton	44,551	464	1.0%	40,834	3,253
Hastings & Prince Edward Counties	5,479	31	0.6%	4,832	616
Huron Perth	4,868	81	1.7%	4,397	390
Kingston Frontenac Lennox & Addington	8,355	31	0.4%	7,855	469
Lambton County	8,429	103	1.2%	7,471	855
Leeds Grenville And Lanark District	5,313	73	1.4%	4,674	566
Middlesex-London	27,917	288	1.0%	25,178	2,451
Niagara Region	30,317	472	1.6%	27,618	2,227
North Bay Parry Sound District	2,603	11	0.4%	2,363	229
Northwestern	3,015	12	0.4%	2,552	451
Ottawa	56,114	675	1.2%	51,749	3,690
Oxford Elgin-St.Thomas	9,799	134	1.4%	8,833	832
Peel Region	162,287	1,066	0.7%	153,218	8,003
Peterborough County-City	4,747	42	0.9%	4,247	458
Porcupine	4,042	35	0.9%	3,640	367
Renfrew County And District	2,612	20	0.8%	2,280	312
Simcoe Muskoka District	30,592	321	1.0%	28,011	2,260
Sudbury And District	8,552	78	0.9%	7,139	1,335
Thunder Bay District	6,297	74	1.2%	5,398	825
Timiskaming	922	8	0.9%	810	104
Toronto	262,658	3,901	1.5%	246,490	12,267
Waterloo Region	37,112	341	0.9%	34,009	2,762
Wellington-Dufferin-Guelph	16,778	135	0.8%	15,541	1,102
Windsor-Essex County	33,316	546	1.6%	30,553	2,217
York Region	92,997	946	1.0%	88,645	3,406
Totals:	1004879	11068	1.10%	932245	61566

Last Updated: 2022-01-26 Time 10:26:34 GMT. Source: CSPaC

---

Justin Trudeau, Prime Minister of Canada said Monday that, “As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.”

---

Watch Patty Hajdu, Minister of Health.

 

 

Chart: SARS2-CoV-2 vaccine candidates in Phase 1-3 plus significant candidates in pre-clinical R&D

 

Candidate	Sponsor	Trial Phase	Institution
bacTRL-Spike	Symvivo	Pre-clinical	Symvivo Corporation
PittCoVacc	UPMC/University of Pittsburgh School of Medicine	Pre-clinical	University of Pittsburgh
V591	University of Pittsburgh’s Center for Vaccine Research	Pre-clinical	University of Pittsburgh; Themis Biosciences; Institut Pasteur
Ii-Key peptide COVID-19 vaccine	Generex Biotechnology	Pre-clinical	Generex
Recombinant vaccine	Vaxart	Pre-clinical	Vaxart
LineaDNA	Takis Biotech	Pre-clinical	Takis Biotech
AdCOVID	Altimmune	Pre-clinical	University of Alabama at Birmingham
T-COVIDTM	Altimmune	Pre-clinical
Protein subunit vaccine	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre	Pre-clinical	University of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine Centre
Adenovirus-based vaccine	ImmunityBio; NantKwest	Pre-clinical
AAVCOVID	Massachusetts Eye and Ear; Massachusetts General Hospital; University of Pennsylvania	Pre-clinical
Recombinant vaccine	Sanofi, Translate Bio	Pre-clinical
HaloVax	Voltron Therapeutics, Inc.; Hoth Therapeutics, Inc.	Pre-clinical	MGH Vaccine and Immunotherapy Center
mRNA-based vaccine	Chulalongkorn University’s Center of Excellence in Vaccine Research and Development	Pre-clinical
HDT-301	University of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp	Pre-clinical
gp96-based vaccine	Heat Biologics	Pre-clinical	University of Miami Miller School of Medicine
ChAd-SARS-CoV-2-S	Washington University School of Medicine in St. Louis	Pre-clinical	Washington University School of Medicine in St. Louis
Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3	Henan Provincial Center for Disease Control and Prevention
CoronaVac	Sinovac	Phase 3	Sinovac Research and Development Co., Ltd.
mRNA-1273	Moderna	Phase 3	Kaiser Permanente Washington Health Research Institute
Ad5-nCoV	CanSino Biologics	Phase 3	Tongji Hospital; Wuhan, China
NVX-CoV2373	Novavax	Phase 2b	Novavax
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3	University of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital
AZD1222/Covishield	The University of Oxford; AstraZeneca; IQVIA; Serum Institute of India	Phase 2/3	The University of Oxford, the Jenner Institute
BNT162	Pfizer, BioNTech	Phase 2/3	Multiple study sites in Europe and North America
Adjuvant recombinant vaccine candidate	Anhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of Sciences	Phase 2
ZyCoV-D	Zydus Cadila	Phase 2	Zydus Cadila
Covaxin	Bharat Biotech; National Institute of Virology	Phase 2
BBIBP-CorV	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 1/2	Henan Provincial Center for Disease Control and Prevention
GRAd-COV2	Genexine	Phase 1/2
Sputnik V	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Phase 1/2	Various
Self-amplifying RNA vaccine	Imperial College London	Phase 1/2	Imperial College London
LUNAR-COV19	Arcturus Therapeutics and Duke-NUS Medical School	Phase 1/2	Duke-NUS Medical School, Singapore
INO-4800	Inovio Pharmaceuticals	Phase 1/2	Center for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, Philadelphia
Ad26.COV2-S	Johnson & Johnson	Phase 1/2	Johnson & Johnson
mRNA-based vaccine	CureVac	Phase 1	CureVac
SCB-2019	GlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax	Phase 1	Linear Clinical Research (Australia)
COVAX-19	Vaxine Pty Ltd.	Phase 1	Royal Adelaide Hospital
Plant-based adjutant COVID-19 vaccine candidate	Medicago; GSK; Dynavax	Phase 1	Medicago
Molecular clamp vaccine	CSL; The University of Queensland	Phase 1
V590	Merck; IAVI	Phase 1
GRAd-COV2	ReiThera; Leukocare; Univercells	Phase 1	Lazzaro Spallanzani National Institute for Infectious Diseases
AdimrSC-2f	Adimmune	Phase 1	Adimmune
mRNA lipid nanoparticle (mRNA-LNP) vaccine	CanSino Biologics, Precision NanoSystems	Early research

 

Chart Data Source: Regulatory Affairs Professionals Society.

 

Read also:

Civil Society aims at children to demystify SARS2 vaccines